Read if you want one stock you can retire on

[brucefan]

[h=2]IMPORTANT ANNOUNCEMENT – March 25, 2020[/h][h=3]Predictive Laboratories has notified the U.S. Food and Drug Administration of its intent to immediately distribute the validated Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test (Assurance AB™) to laboratories and healthcare workers at the point-of-care in the U.S.[/h]

[h=2]“The overwhelming need for a quick and accurate test for this pandemic is obvious. Focusing on an antibody test helps accelerate results and protect healthcare workers. The Assurance AB™ test is a valuable tool for truly understanding the spread of COVID-19 in the U.S.”[/h]– John Nelson, M.D.
Former president of the American Medical Association, Predictive scientific advisory board member https://predictivelabs.com/assurance-ab-covid19/
https://predictivelabs.com/wp-content/uploads/2020/03/Assurance-AB-Manufacturing-Overview.pdf

 

[brucefan]

Predictive Technology Group Announces Launch of Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test for Use by Laboratories and Healthcare Workers at the Point of Care







GlobeNewswireMarch 25, 2020





Assurance AB™ is a single-use, self-contained SARS-CoV-2 (COVID-19) antibody detection test that provides results in 15-minutes.
SALT LAKE CITY, March 25, 2020 (GLOBE NEWSWIRE) -- Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics today announced that in response to the demand for high volume test availability for the SARS-CoV-2 (COVID-19) global pandemic, Predictive Laboratories, a wholly-owned subsidiary of The Company has notified theU.S. Food and Drug Administrationof its intent to immediately distribute the validatedAssurance AB™COVID-19 IgM/IgG Rapid Antibody Test(Assurance AB)test to laboratories and healthcare workers at the point-of-care in the U.S.

TheAssurance ABtest was developed to detect the presence of IgM and/or IgG antibodies to the SARS-CoV-2 virus. The test requires only a fingerstick to sample an individual’s blood which is then placed on the self-contained test device. The test takes 15-minutes to display results. The test results indicate the presence of antibodies associated with the SARS-CoV-2 virus.
“Our company is committed to help with the global challenge of testing for the COVID-19 virus,” said Bradley Robinson, CEO of Predictive Technology Group. “Testing strategies for the pandemic are fluid and changing daily. We have worked diligently with our partners who have experience in testing tens of millions of patients worldwide. We appreciate their assistance in allocating resources and transferring vital knowledge for identifying individuals that have had an immune reaction and developed antibodies in response to virus exposure. Domestic and international governmental agencies, healthcare groups, pharmacies and employers have shown a strong interest in our test,” added Robinson. The Company will distribute theAssurance ABtest through its wholly-owned subsidiary Predictive Laboratories, Inc., a CLIA certified and CAP accredited laboratory.
John Nelson M.D., former president of the American Medical Association and Predictive scientific advisory board member, commented, “The overwhelming need for a quick and accurate test for this pandemic is obvious. Focusing on an antibody test helps accelerate results and protect healthcare workers. TheAssurance ABtest is a valuable tool for truly understanding the spread of COVID-19 in the U.S.”
Assurance ABcan help authorities, employers and healthcare workers make informed decisions on whether or not to continue precautions. Point of care serology testing may allow individuals with antibodies the confidence to go back to the workplace and engage in their communities.
Additional advantages of theAssurance ABtest include:

• inexpensive test with results in 15 minutes
• antibody testing is less complex and remedies potential false negative results common in nasopharyngeal swab sampling
• sample collection type (blood droplets) nearly eliminates the risk of spreading the virus to healthcare workers administering tests and/or to laboratory personnel who handle the submitted samples

Because of the rapid spread of the COVID-19 virus, several states includingCalifornia and New Yorkhave recently expressedimmediate need for rapid antibody testing. While there are benefits to viral testing, serology antibody testing allows patients to know if they have been exposed to the virus and if they have developed antibodies typically associated with immunity.
Assurance ABCOVID-19 IgM/IgG Rapid Antibody Test is being manufactured in cooperation with Jiangsu Dablood Pharmaceutical CO, Ltd. Dablood Pharmaceutical has successfully distributed 38 million tests to date throughout Asia and Europe. To the best of Predictive’s knowledge, Dablood Pharmaceutical is one of very few companies approved by the Chinese government to co-develop and manufacture rapid antibody tests. Dablood Pharmaceutical is one of the largest diagnostic kit manufacturers in China and is currently producing up to 1.5 million units of the rapid antibody test per day in China. Predictive evaluated other potential developers and suppliers and believes Dablood Pharmaceutical provides not only existing inventory, its high-volume production capacity enables them to rapidly increase production to provide high-quality tests to meet rapidly expanding global demand. Dablood Pharmaceutical has been recognized by the Chinese government for its effort of developing and producing testing products to help the detect the COVID-19 and has received approval for distribution of its test across the domestic Chinese market and the European Union with a CE mark.

Predictive is also pursuing procurement authorization through the Biomedical Advance Research and Development Authority (BARDA) under the Office of the Assistant Secretary for Preparedness and Response (ASPR) in Health and Human Services (HHS). The Company cautions that if the federal government decides to restrict adequate reimbursement or the foreign import of products manufactured in Asia, the Company will not be able to provide access to these tests in the U.S.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visithttps://www.globenewswire.com/Track...ikKUlgzgL3xYJ57CuJRSmO8AV1mXJ_K83VWa88rC7vqw=www.predtechgroup.com.
About Predictive Laboratories, Inc.
Predictive Laboratories a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) is focused on hard-to-detect diseases. The laboratory is equipped with state-of-the-art equipment for any next-generation sequencing experiments including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies.
www.predictivelabs.com
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Predictive Laboratories
institutional@predictivelabs.com
commercial@predictivelabs.com
info@predictivelabs.com
855-497-3636
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568

 

[RapStar]

I really hope they can get this to market and faster than anyone else doing the same. Lots of rumors flying around about people having similar kits. Let's catch a break here!

 

[Bruins4Life]

93 cents today

Up over 50% on the day.

I tried to buy at .81 but my rrsp wont allow me to access that market.

 

[Bruins4Life]

Closed at 1.03

 

[brucefan]

if anyone is wondering why we are under pressure today, another hit piece was published by the same group

hate those bastards

 

[okie77]

Yeah this is the link. No idea the validity of it all. Obviously hope it's bullshit. Once again e will ride out the shitstorm I guess.
https://hindenburgresearch.com/predictive-covid/

 

[mountain]

RCL- Royal Caribbean Cruise LTD. Sitting on 1.4 billion in cash, just secured a 2 billion line of credit. Well run company. Bought some at 19.75 last week and it took off to $43 but has dialed back to $35 since cruise lines are exempt from the stimulus package..they don't need it. Strong company who hit $135 a couple months ago. Great opportunity. What bank approves a 2 billion dollar line of credit to a weak company?

May teeter back and forth short term but definitely worth a look

 

[TheFalls]

Yeah this is the link. No idea the validity of it all. Obviously hope it's bullshit. Once again e will ride out the shitstorm I guess.
https://hindenburgresearch.com/predictive-covid/

you can shut the studio down right now if this is valid...

As of the latest quarter-end, Predictive had only $255,502 (figure not in thousands) of cash compared to current liabilities of almost $10 million. [Pg. 2] It had burned $9.9 million of operating cash in the latest 6-month period and reported a net loss of $33.9 million during the same time frame.

The company appears to be on life support. To survive, it has been relying on private loans. Per the latest financials, these loans were recently converted into 12,947,833 shares of common stock. [Pg. 40]

 

[brucefan]

Not much panic with this report .

Could it be because its all bullshit?

 

[brucefan]

	[FONT=&quot]The market will continue to follow the pandemics ebb and flow [/FONT]
The world economy is getting crushed,but opportunities in our market will surface as virus cases shrink
	We are watching many listed stocks that have been slaughtered. We still favor our 2 micro-caps -PRED and ELGL If you already are a PRED shareholder you already know the story. The company continues to be attacked by endless "Black Swans" In our opinion, PRED is on a launch pad ready for lift off when it gets the right fuel mixture. Their stem cell business we believe took off in feb 2020 because a China medical staff found that Mesenchymal stem cells help patients with coronavirus disease COVID19. On the 25th of March, PRED announced the launch of Assurance AB (tm) COVID-19 IgM/IgG Rapid Antibody detection test that provides results in 15 minutes. This test will be used by lab and healthcare workers at the point of care. The potential of this product alone equals a "moon shot!" If that was not enough to excite the wary? It is believed that since everyone is "playing house" that the result could be a baby boom! The results from a possible baby boom could also result in host of fertility issues and testing for endometriosis. Don't forget PRED has recently introduced test kits for both! There are many things in the works that near term could also generate additional interest, which in turn should create additional stock appreciation. We are the first to agree that PRED has been a "dog", but all dogs have their day! If you own PRED at higher prices it surely would be smart to average down at current levels. Please keep in mind that "test kit" news is everywhere and there is plenty of room for many players. We have been told that PRED has exclusive rights for the sale of their product in the USA. In our opinion , there will a need for 100 million test kits and that does not take into future needs. If PRED's kit becomes a standard the profit potential just from this division of PRED could be mind-boggling. Please take some time and review their updated website and read all the current news. We remain committed to our recommendation that PRED is a Strong Buy at current levels. http://www.predtechgroup.com Food for thought: We understand that the Corona virus has created a pandemic, but realize that during 2018 80,000 US citizens died from the flu !! The media hates Trump and this just another opportunity to destroy this President. Please keep in mind that 90 people die every day in car accidents. Around 90 people die from accidents within their homes per day. In America 100 people die from gun violence/day. Everyday almost 200 people die from drug overdose/day. REALITY IS REALITY!

 

[brucefan]

[FONT=&quot]Company provides formal response to misleading recently published short report[/FONT]
[FONT=&quot]SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, and its manufacturing partner, Jiangsu Dablood Pharmaceutical CO, Ltd. (Dablood), a partner entity of Da An Gene Co., Ltd., today made several updates and progress reports on its Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test (Assurance AB) intended for laboratories and healthcare workers at the point-of-care in the U.S.
[/FONT]
[FONT=&quot]“An opinion piece critical of Predictive was posted online last week by individually unidentified author(s) who admitted they have taken a short position in shares of The Company,” said John Sorrentino, chairman of Predictive Technology Group. “We encourage every reader to do their own due diligence and review the documents posted today on Predictive Laboratories’ website. The author(s), hiding behind anonymity – and attempts to disclaim – also warn that ‘Hindenburg Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information.’ Because the opinion piece itself warns readers of its short position-based bias and its unwillingness to guarantee the accuracy of any ‘information’ it espouses, The Company will not dignify the opinion piece with a point-by-point response, however we felt compelled to address a few egregious misrepresentations and untruths.”[/FONT]
[FONT=&quot]The opinion piece asserts a material falsehood that “Dablood is NOT one of the companies approved by the Chinese government to offer COVID-19 tests. The official list of approved COVID-19 test providers is published by the Chinese government, was updated as of March 17th, and does not include Dablood or its affiliates.” If properly investigated, one can find that #5 on the referenced list is Da An Gene Co., Ltd. Guangzhou Darui Biotechnology, a subsidiary of Da An Gene Co., Ltd., has joint venture entity in Dablood. As such, Dablood operates under the Da An Gene Co., Ltd. license.[/FONT]
[FONT=&quot]Regarding Predictive’s formal request for Emergency Use Authorization (EUA) from the FDA to distribute Assurance AB, the opinion piece states, in part, that “Predictive has no specific approval from requisite U.S. authorities to provide this test.” The Company views this statement as simply not true. [/FONT]
[FONT=&quot]“The FDA’s recent guidance on COVID-19 antibody (i.e. serological) diagnostic tests clearly allows manufacturers to market these tests in the United States to laboratories and healthcare workers at the point of care, so long as the tests have been validated and notification is provided to the FDA,” said Bradley Robinson, CEO of Predictive Technology Group. “The Predictive/Dablood test meets these criteria. Additionally, The Company has formally submitted an EUA with the FDA. If granted, this would provide Predictive the ability to market the test for in-home use.”[/FONT]
[FONT=&quot]Predictive Laboratories, Inc., a wholly-owned entity of The Company, operates a CLIA-certified and CAP-accredited laboratory which is responsible for the distribution of the Assurance AB. Predictive Laboratories has updated its website to include the following:[/FONT]

• Dablood Board of Directors response to the erroneous and misleading Hindenburg opinion piece published on March 27, 2020
• FDA confirmation receipt of EUA application
• Representative of Foreign Manufacturer Notice from Dablood to the FDA
• Manufacturer FDA EUA Notification from Dablood to the FDA
• U.S. Agent Retainer Agreement

[FONT=&quot]“The Hindenburg piece repeatedly and inaccurately attempts to cast Predictive solely as a stem cell company while ignoring The Company’s other diagnostic assets, such as ARTguideTM and FertilityDXTM, and its recently announced diagnostic assay collaboration with Atrin Pharmaceuticals. In this context, a COVID-19 rapid antibody test is a logical addition to Predictive’s portfolio. Nevertheless, they attempt to cast Predictive as simply a stem cell company,” said Robinson. “Predictive encourages thoughtful investors to consider the motives of these anonymous authors when assessing the truthfulness and accuracy of any statement or report in the opinion piece. Predictive will pursue any and all legal actions against individuals and entities who intentionally mislead Predictive stakeholders.”[/FONT]
[FONT=&quot]“The response to the announcement of Assurance AB (March 25, 2020) has been very strong,” continued Robinson. “In particular, both international and domestic governmental agencies have expressed strong interest in how rapid antibody testing can help with the public health response to this critical pandemic. We want to acknowledge the tireless activities by our employees and partners in developing a tool that can be a part of solving this global health crisis.”[/FONT]
[FONT=&quot][/FONT]
[FONT=&quot]About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit [url]www.predtechgroup.com[/URL].
About Predictive Laboratories, Inc.
Predictive Laboratories a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) is focused on hard-to-detect diseases. The laboratory is equipped with state-of-the-art equipment for any next-generation sequencing experiments including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies.
www.predictivelabs.com
[/FONT]

 

[okie77]

https://predictivelabs.com/assurance-ab-covid19-igm-igg-antibody-test/

 

[Bruins4Life]

Closed at 86 cents.

 

[ECC]

Did Abbott Laboratories (ABT) beat them to the punch?
Product already being used and results within 5-15 minutes

 

[brucefan]

Did Abbott Laboratories (ABT) beat them to the punch?
Product already being used and results within 5-15 minutes

Other then toilet paper, is there another product in higher demand right now in the world?

 

[ECC]

Other then toilet paper, is there another product in higher demand right now in the world?

:think2: valid point

 

[valium]

Pred has a habit of making a great press release and then nothing happens on the follow up.

 

[brucefan]

[h=1]Predictive Technology Group Announces Distribution Agreement with Wellgistics, LLC for Its Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test for Use by Laboratories and Healthcare Workers at the Point-of-Care[/h][h=2][/h][FONT=&quot]https://www.globenewswire.com/news-...or-Use-by-Laboratories-and-Healthcare-W.html#[FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT]Email [FONT=&quot][/FONT]Print Friendly [FONT=&quot][/FONT]Share
April 03, 2020 08:00 ET | Source: Predictive Technology Group Inc


SALT LAKE CITY, April 03, 2020 (GLOBE NEWSWIRE) -- Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced a distribution agreement between its subsidiary, Predictive Laboratories and Wellgistics, LLC of Lakeland, Florida for distribution in the U.S. of its Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test (Assurance AB) intended for use by laboratories and healthcare workers at the point-of-care in the U.S.

Wellgistics, LLC, is one of the fastest growing wholesale pharmaceutical distributors in the United States. It is a logistics leader in the complex healthcare supply chain. Wellgistics is licensed in all 50 states as a Pharmaceutical Wholesale Distributor and is also licensed or permitted as Third-Party Logistics provider in all states. Its distribution facility, located in Lakeland, FL, is VAWDÒ accredited by the National Association of Boards of Pharmacy.
“From the onset of this global crisis, the Wellgistics’ leadership team has placed its sole focus on finding solutions for America. We felt confident that our competency in healthcare and pharmaceutical distribution would be sought out by product innovators to assist in delivering critically needed supplies throughout the country,” said Brian Norton, CEO of Wellgistics.
“Our newly established alliance with Predictive Laboratories allows us to leverage our complex distribution network in delivering the life-saving Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test to healthcare professionals all across the country. We are keenly aware and very impressed with the extensive steps taken by Predictive to ensure the highest levels of quality in their dual channel IgM/IgG product, which we believe will become the “gold standard” in the marketplace,” said Norton.
“We are pleased to partner with Wellgistics. They are an ideal partner and are able to scale and serve the most critical needs in the face of this global pandemic. Wellgistics’ logistics, expertise and infrastructure has demonstrated the ability to efficiently move products from around the world to the U.S. market and was an important component in our decision to partner with them. We are in production in advance of Wellgistics' purchase orders and will update stakeholders on details over the next few days,” said Bradley Robinson, CEO of Predictive Technology Group. “We will support Wellgistics, their team and customers with Predictive Laboratories’ full scientific, operational and service team members,” added Robinson.
About the Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test:
The Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test is a rapid test for the qualitative detection of IgM and IgG antibodies associated with the SARS-CoV-2 virus. Assurance AB is a single-use, self-contained test that provides results in 15 minutes, helping authorities, employers and healthcare workers make informed decisions to contain the spread of COVID-19.
Assurance AB is intended for individuals who display signs and symptoms of COVID-19, individuals who were exposed to someone infected with COVID-19, or individuals who want qualitative information about whether or not they have IgM or IgG antibodies. Assurance AB is for use by laboratories and healthcare workers at the point-of-care.
What is antibody testing?
Antibody assays have the ability to detect past infections and indicate probable immunity. Antibodies are long-lasting and may be detected in the bloodstream several years after infection.
Assurance AB detects the presence of antibodies IgM and IgG, developed in response to the SARS-CoV-2 virus. The antibody and its relative levels may be used to indicate the stage of infection and estimate time since exposure to the virus for contact tracing.

• IgM: develop EARLY after SARS-CoV-2 virus exposure
• IgG: develop LATER after SARS-CoV-2 virus exposure; indicates long-term immunity

Assurance AB Benefits

• Results in 15 minutes
• Highly accurate (92% sensitivity (CI95% 89.4-95.7%); 100% specificity (CI95% 96.8-100%))
• NO laboratory equipment required
• NO specialized training required, easy-to-use
• Reduces risk of spreading the virus to healthcare workers administering tests or technicians processing tests
• Provides actionable information to all patients to help determine if a COVID-19 viral PCR test is needed
• Provides insightful information for when it is safe for individuals to go back to work and resume normal activities of daily life
• Test kits can be stored and used at room temperature
• Antibody testing is improved over nasopharyngeal swab testing by the fact that antibodies are more uniformly present in blood sampling

About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.
Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictive’s tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit [url]https://predtechgroup.com/[/URL]
About Predictive Laboratories, Inc.
Predictive Laboratories’ molecular and genetic diagnostics focus on hard-to-diagnose and hard-to-detect diseases. Leveraging its vast genetic library, Predictive offers earlier detection of a variety of diseases through genetic assessments to guide personalized precision medicine.
Equipped with a state-of-the-art CAP and CLIA accredited laboratory, Predictive operations perform next-generation sequencing experiments, including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies. Predictive arms physicians with the most robust diagnostic tools to provide personalized precision treatment for their patients. For more information, visit [url]www.predictivelabs.com[/URL]
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Predictive Laboratories
Info@predictivelabs.com
855-497-3636
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568
[/FONT]

 

[Bozzie]

Nice move Bruce!